Background: Alzheimer’s disease (AD) is the most common form of dementia. The process of
AD can begin 20 years before any symptom of cognitive loss. Thus, the development of systems for early
diagnosis and prevention is very important. The mechanism of AD is still under debate. Nevertheless,
higher levels of glycated albumin in cerebrospinal fluid and plasma are observed in AD patients. Therefore,
glycated albumin could be a biomarker of AD development.
Methods: Electrochemical biosensor for direct determination of glycated albumin was based on thiol
derivative of pentetic acid (DTPA) complex with Cu(II) created on gold electrode surface. His-tagged
domains of Receptors for Advanced Glycation End Products (RAGE) were applied as analytical active
element for glycated albumin recognition. The binding of glycated albumin by His6- RAGE domains was
monitored using Osteryoung square - wave voltammetry.
Results: Electrodes modified with His6 - RAGE VC1 natural domain generated decrease of Cu(II) redox
currents in the presence of glycated albumin. Human albumin, Aβ 1-40 and S100B protein caused negligible
influence on biosensors responses towards glycated albumin. The detection limits were: 2.3 pM, 1.1
pM, 2.9 pM and 3.1 pM in the presence of: buffer, buffer + albumin, buffer + S100B, buffer + Aβ1-40 ,
Conclusion: The presented electrochemical biosensor was successfully applied for the determination of
glycated albumin. Considering analytical parameters such as good selectivity and sensitivity in pM range,
biosensor could be recommended as an analytical tool for medical samples analysis.